Heart failure & cardiomyopathiesCohort study
Erythropoietic Response After Intravenous Iron in Patients with Heart Failure and Reduced Ejection Fraction with and Without Background Treatment with Sodium–Glucose Cotransporter 2 Inhibitors
- Retrospective cohort study
- single-centre
- matched for age and sex
Authors' conclusion
Combined treatment with IV iron and background SGLT2i was associated with a greater increase in haemoglobin and haematocrit than IV iron without background SGLT2i.
Study context
- Population
- Heart failure with reduced ejection fraction (HFrEF) patients with iron deficiency treated with intravenous (IV) ironmatched cohort
- Participants
- 60 vs 60
- Exposure
- IV iron with background SGLT2i vs IV iron without SGLT2i
- SGLT2i usersn = 60
- SGLT2i non-usersn = 60reference
- Outcome
- Changes in haemoglobin, haematocrit and iron biomarkers
Main finding
As reported in the abstract
- haemoglobin; adjusted for all baseline differences
- difference +0.57 g/dl (95% CI 0.04–1.10); P = 0.036
- haematocrit; adjusted for all baseline differences
- difference +1.64 % (95% CI 0.18–3.11); P = 0.029
Observational data: associations, not effects.
Secondary outcomes
Natriuretic peptides, kidney function, HF-associated outcomes
- No significant differences
Original publication
Erythropoietic Response After Intravenous Iron in Patients with Heart Failure and Reduced Ejection Fraction with and Without Background Treatment with Sodium–Glucose Cotransporter 2 Inhibitors. Eur J Heart Fail. Published 24 August 2023. doi:10.1002/ejhf.2992
Summarised from the published abstract; every number is checked against it